In an attempt to establish a model for hepatitis C virus (HCV) infection, we produced mice transgenic for the HCV envelope genes, E1 and E2, under the control of a regulatory element from hepatitis B virus. Fl-generation mice from the established founders demonstrated expression of both E1 and E2 proteins as glycosylated forms in their organs including the liver. Immunostaining revealed the localization of envelope proteins principally in the cytoplasm of hepatocytes around the hepatic central veins. Furthermore, E1 and E2 proteins were shown by immunoprecipitation to be associated with each other in the mouse liver. There was no evidence of tissue pathology in the mouse liver up to 16 months of age, suggesting that E1 and E2 proteins per se may not have direct pathogenic effects. Our results demonstrate the first successful expression of HCV gene products in the mouse liver and the association of in vivo expressed HCV envelope proteins. This transgenic mouse would be a good model to study the virus-ceU interactions of HCV such as intracellular transport and assembly of envelope proteins. Also it may be a good model system to determine the role of these proteins in the pathogenesis of hepatitis or extra-hepatic manifestations in HCV infection by the introduction of cytotoxic T lymphocytes specific for the envelope proteins.
Introduction
Since the identification of hepatitis C virus (HCV) genomic cDNA (Choo et al., 1989) , clinical aspects of HCV infection have been described in detail by the use of simple immunoassays for HCV antibodies (Alter et al., 1989; Chiba et al., 1991; Esteban et al., 1990) or PCR (Weiner et al., 1990) . Genetic variations have been extensively studied in HCV envelope gene sequences (Kato et al., 1993; Taniguchi et al., 1993) and the influence of HCV genotype on the long-term response to interferon therapy of chronic hepatitis C has been reported (Yoshioka et al., 1992) . On the other hand, several strategies have been used to elucidate the processing of the polyprotein which is translated from the HCV genome (Houghton et al., 1991; and to characterize individual proteins. These include in vitro translation (Hijikata et al., 1991) , expression in bacteria (Muraiso et al., 1990) , insect cells and mammalian cells (Grakoui et al., 1993; Harada et al., 1991; Kohara et al., 1992;  * Author for correspondence. Fax +813 3812 5063. e-mail kkoike-tky@umin.u-tokyo.ac.jp Lanford et al., 1993; Matsuura et al., 1992; Ralston et al., 1993) . Studies have also been made of the expression of HCV envelope proteins (Grakoui et al., 1993; Lanford et al., 1993; Ralston et al., 1993) which revealed that the two putative envelope proteins, E1 and E2, are associated at their N termini in mammalian cells (Matsuura et al., 1994) . However, very little is known about the role of envelope proteins in virus-cell interactions, particularly in the early stage of viral infection or cell surface alterations.
The most important features of HCV are that, like hepatitis B virus (HBV), it frequently causes persistent infection lasting more than 30 years and is accompanied by inflammation in the liver which finally leads to the development of hepatocellular carcinoma (HCC) (Houghton et al., 1991 ; Saito et al., 1990) . It is therefore important to elucidate how HCV infects hepatocytes and escapes the host inamune system, especially neutralizing antibodies against viral envelope proteins. As the first step in such an approach, we have reported the expression of HCV envelope proteins in insect cells or monkey cells (Matsuura et al., , 1994 . We have also reported, as a model for HBV infection, transgenic mice carrying the HBx gene of HBV under the control of its own promoter and shown that the HBx protein plays an 0001-3376 © 1995 SGM important role in the pathogenesis of HCC (Kim et al., 1989; Koike et al., 1994a) . In the present study, we describe transgenic mouse lineages that have HCV envelope genes under the control of the same HBV gene regulatory elements. These mice showed stable expression of the HCV envelope proteins, E1 and E2, which were associated with each other in the liver.
Methods
Construction ofplasmids. Enzymes and linkers were purchased from New England Biolabs. To ensure high-level expression in the liver, we placed the HCV envelope genes under the control of HBV regulatory elements which have been shown to allow high-level expression of a HBV gene in transgenic mice without interfering with mouse development (Koike et al., 1994a) . For this purpose, an expression vector pBEPBglII was derived from plasmid pUCHBx (Koike et al., 1994b) . Briefly, the open reading frame of the HBx protein was replaced with a BgllI linker in the plasmid pUCHBx using PCR. The resulting plasmid, pBEPBgllI, has an enhancer, promoter and polyadenylation signal from HBV ( Fig. 1) .
A 1.8 kb fragment containing the coding regions of E1 and E2 was cut from the plasmid pSR825x (Matsuura et al., 1994) Production of transgenic mice. A 2"5 kb EcoRI-PstI fragment from pBEP825 ( Fig. 1 ) was purified by polyacrylamide gel electrophoresis (PAGE) and microinjected into mouse embryos from the CD1 strain (Charles River Japan) as described previously .
Transgenic mice were identified by subjecting 1 ~tg of tail DNA to amplification by PCR using two sets of oligonucleotides as primers. Oligonucleotides T3 (5' CACTACGACATTACGACGCCY) and T4 (5' CCGTGGGCGACCAGTTCATC 3') were used to amplify a 227 bp fragment from the E1 gene. Oligonucleotides T5 (5' CTCACGTCCCTCTTTAGACC 3") and T6 (5' TACGATACCA-CACTGTCGAC 3') were used to amplify a 297 bp fragment from the E2 gene fragment. PCR amplification was performed as described previously (Yotsuyanagi et al., 1993) with the following parameters: 30 cycles consisting of 94 °C for 2 min, 55 °C for 1 min and 62 °C for 1.5 min. To characterize the founders further, Southern blotting was performed as described previously .
Antibodies. Antibodies used in this study are as follows: rabbit anti-E1 serum, mouse monoclonal anti-E2 antibodies, and rabbit anti-E2 serum. Monoclonal antibodies were raised against partially purified recombinant E1 or E2 protein expressed by baculoviruses. Polyclonal rabbit antibodies were prepared using recombinant vaccinia viruses (Matsuura et al., 1994) .
Western blotting and immunoprecipitation. Whole tissue homogenates
were resuspended in Western sample buffer (5 % 2-mercaptoethanol, 2% SDS, 62-5mM-Tris-HC1, 1 mM-EDTA, 10% glycerol). Appropriate amounts of proteins were then subjected to 10% SDS-PAGE and electro-transferred to nitrocellulose membrane (Schleicher & Schuell) as described previously (Koike et al., 1994b) . The filter was then reacted with primary antibodies, followed by an appropriate secondary biotinylated IgG (Vector Laboratories), and visualized using an avidin-biotin peroxidase method (Vectastain kit; Vector Laboratories) and an ECL kit (Amersham). For immunoprecipitation studies, liver tissues or mouse serum were homogenized in RIPA buffer (50 mM-Tris-HC1 pH 7.4, 150 mM-sodium chloride, 1% Triton-X100, 1% sodium deoxycholate, 0.1% SDS), and precipitated with anti-E1 or anti-E2 monoclonal antibodies. Resulting pellets were then subjected to Western blotting.
Immunostaining. Frozen liver sections (5 ~m thick) were fixed for 5 min in ice-cold acetone. Anti-E1, anti-E2 or normal rabbit serum was used as primary antibody. For detection, biotinylated anti-rabbit IgG followed by avidi~biotin peroxidase (Vector Laboratories) was used. Specificity control of immunostaining was carried out as follows: liver tissues and other organs from a normal littermate mouse were tested with immune serum. Normal rabbit sera were tested with transgenic mouse liver.
Results

Transgenic mouse lineages
Three transgenic mouse lineages which had HCV envelope genes were derived (El01, Ell8 and E139). Southern blotting of StuI-digested genomic DNA revealed a distinct integration pattern for each lineage (data not shown). The observed pattern is compatible with the presence of at least one full-length transgene. The integrated transgenes were successfully transmitted to offspring, and F 1 mice from the lineages El01 and E139 were investigated in this study.
Expression of envelope proteins
After confirmation o f the presence o f transcripts from the H C V envelope genes by the reverse t r a n s c r i p t i o n -P C R ( R T -P C R ) method, we examined the expression o f envelope proteins in liver tissue by Western blotting. Western blotting analysis with anti-E1 rabbit serum on lysates from the liver of the lineages El01 and E139 d e m o n s t r a t e d the E1 protein b a n d of a b o u t 35 k D a (Lin et al., 1994) c o m p a t i b l e with the size o f the E1 protein expressed in HCV-transfected H e p G 2 cells (Fig. 2 a) . The E2 protein was also d e m o n s t r a t e d in liver tissue from these lineages by Western blotting with mouse m o n oclonal a n t i b o d y as a b a n d o f 58 k D a as we previously described using cultured m a m m a l i a n cells ( M a t s u u r a et al., 1994) (Fig. 3) .
To determine whether the envelope proteins were glycosylated or not, we treated total protein lysate from transgenic mouse liver with N-glycanase ( G e n z y m e C o r p o r a t i o n ) according to the m a n u f a c t u r e r ' s instruc- (Fig. 3) . Total protein p r e p a r a t i o n s from tissues such as the brain, salivary glands, lung, liver, intestine, spleen and kidney from mice o f lineages 101 and 139 were then i m m u n o b l o t t e d with anti-E1 rabbit serum or anti-E2 mouse m o n o c l o n a l a n t i b o d y to study the tissue distribution of the envelope proteins. E1 protein was detected in the salivary glands, lung, liver, intestine and kidney, and E2 protein was detected in the salivary glands and liver. O f these organs, the liver had the highest levels of expression (Fig. 4) . 
Association of E1 and E2 proteins
To study the interaction of HCV envelope proteins in the liver, lysates from transgenic mouse liver were immunoprecipitated by anti-E1 or anti-E2 antibody, and subjected to Western blotting with anti-E1 rabbit serum or anti-E2 mouse monoclonal antibody. A 35 kDa E1 protein was precipitated not only by anti-E1 antibody but also by anti-E2 antibody (Fig. 5 a) . Similarly, anti-E2 antibody detected a 58 kDa protein in the precipitate produced by anti-E1 antibody as well as in that produced by anti-E2 antibody (Fig. 5 b) . These results indicate that E1 and E2 envelope proteins were associated with each other in vivo.
Immunostaining and histological findings
Successful detection of E1 and E2 proteins as glycosylated proteins of the anticipated sizes further prompted us to explore their tissue localization by immunostaining. Frozen sections stained with anti-El rabbit polyclonal antiserum revealed the expression of E1 protein in hepatocytes located principally around the central veins in the transgenic mouse liver (Fig. 6 a) . Generally, about 15-20 % of hepatocytes which were located around the central veins showed relatively higher levels of E 1 protein compared to those in the surrounding area. Higher magnification revealed that E1 protein was detected mainly in the cytoplasm of hepatocytes but was also seen in the nuclei of some hepatocytes (Fig. 6 b) . Staining with anti-E2 rabbit serum demonstrated that the expression pattern of the E2 protein was similar to that of the E1 protein in hepatocytes around the central veins (Fig. 6 c) . Control mouse liver did not stain with anti-E1 or anti-E2 rabbit serum and transgenic mouse liver did not show staining with normal rabbit serum (Fig. 6d) .
No histological changes such as hepatocyte necrosis, infiltration of lymphocytes, degeneration, preneoplastic foci or neoplasia have been observed up to 16 months of age.
Absence of envelope proteins in transgenic mouse sera
To investigate the extracellular secretion of HCV envelope proteins E1 and E2 we examined sera from the transgenic mice. Serum samples from the two lineages (n = 10; age 1 to 18 months) were immunoprecipitated by anti-E1 rabbit serum or anti-E2 monoclonal antibody and then subjected to Western blotting with anti-E1 rabbit serum or another anti-E2 mouse monoclonal antibody. Neither El antigen of 35 kDa nor E2 antigen of 58 kDa could be detected (data not shown).
Discussion
Owing to the lack of experimental animal model systems other than chimpanzees, studies on the mechanisms of infection, development of protective agents or pathogenesis of HCC in HCV infection have been hampered. As experimental animal models for viral hepatitis, transgenic mice have been reported into which subgenomic or genomic DNA from HBV (Araki et al., 1989; Chisari et al., 1986; Farza et al., 1988; Koike et al., 1994 a) or hepatitis delta virus (Guilhot et al., 1994) was introduced. However, a transgenic mouse which has cDNA of the HCV genome has not been described previously. Recently, in vivo transfection of HCV cDNA into rat liver has been reported (Takehara et aI., 1995) .
However, the expression of HCV genes in those rats was transient and ambiguous. In the present study, we have sought to express the HCV E1 and E2 proteins in the liver of mice to mimic human HCV infection. Our transgenic mice show unambiguous expression of HCV gene products in the liver. The sizes of E1 and E2 envelope proteins expressed in our transgenic mice were 35 kDa and 58 kDa, respect-ively. The size of 35 kDa for the E1 protein is consistent with the previous results obtained using mammalian cultured cells (Grakoui et al., 1993; Matsuura et al., 1992) , indicating that E1 protein is fully glycosylated as in vivo. On the other hand, E2 proteins of different sizes ranging from 58 to 74 kDa have been identified in an in vitro translation system and in animal cells (Grakoui et al., 1993; Hijikata et al., 1991; Lanford et al., 1993; Matsuura et al., 1994; Ralston et al., 1993; Selby et al., 1993 ; Spaete et al., 1992; Tomei et al., 1993) . In addition, it has been reported recently that there is another cleavage site at amino acid residues 746/747 which results in the production of two distinct E2 proteins with different C termini (Lin et al., 1994; Mizushima et al., 1994) . When the E2 gene was expressed with our HCV cDNA in various mammalian cultured cells, a 60 kDa protein was the major E2 protein (Matsuura et al., 1994) . Also detected was a 58 kDa fully glycosylated E2 product, when we used a cDNA clone spanning aa 155-742 (Matsuura et al., 1994) . The E2 protein of 58 kDa detected in our transgenic mice is therefore considered to be fully glycosylated and processed correctly in vivo as well as in cultured cell studies.
In the present study, E 1 and E2 envelope proteins were coprecipitated by either anti-E1 or anti-E2 antibody in the transgenic liver cells. Association of E1 and E2 proteins has been previously reported in insect cells (Lanford et al., 1993; Matsuura et al., 1994) or mammalian cells (Grakoui et al., 1993; Ralston et al., 1993) . It is not clear yet whether the association of these two proteins is mediated by non-covalent linkage (Matsuura et al., 1994; Ralston et al., 1993) or by disulphide bonds (Grakoui et al., 1993) . This association is suggested to occur through their N-terminal portions (Matsuura et al., 1994) , but precise interaction sites on the proteins have not yet been determined. It is noteworthy that not only the production and processing of envelope proteins but also the association of the two proteins was observed in the transgenic mouse liver. Analysis of the behaviour of envelope proteins in animal hepatocytes, whose functions are regulated through interactions with a number of factors and surrounding cells, will give us useful and meaningful information on the behaviour of these polypeptides in the human liver. Since the El-E2 complexes are considered to be more immunogenic than the single polypeptide and may generate protective immunity in chimpanzees (Choo et al., 1994) , this transgenic mouse system would provide a good model for analyses of immune responses to the El-E2 complexes.
To express HCV envelope genes efficiently in mouse liver, we employed an expression vector which was derived from the HBV genome. This vector includes the enhancer I of HBV, the promoter of the HBx gene and the polyadenylation signal of HBV, which have been shown to allow a high level expression of the HBx gene and subsequent development of HCC in transgenic mice (Koike et aI., 1994a) . In the present study, HCV genes placed downstream of these HBV-regulatory elements demonstrated substantial levels of expression. Two lineages of the transgenic mouse showed identical distribution patterns of transgene expression and no development disturbance of the mice was observed. Strong liver-specific transcriptional promoters are not necessarily adequate for establishing transgenic mice, since high-level expression is occasionally lethal to the mouse fetus. Surviving transgenic mice show low levels of transgene expression. The use of this expression vector may be a reason for our efficient establishment of transgenic mice with high levels of HCV proteins as was the case with the HBx gene. This expression vector system is suitable for exerting high levels of gene expression in the mouse liver without disturbance of mouse development.
HCV envelope proteins were not uniformly distributed in the liver tissue. They were principally localized in hepatocytes which were around the central veins in the liver of transgenic mice. Tissue distribution studies revealed that the liver and kidney were the preferential organs for expression. Such an expression pattern was also observed in the transgenic mouse in which the HBx gene of HBV was driven by the same, authentic regulatory elements (Koike et al., 1994a) . The regulatory element of the HBx gene is likely to focus the expression of its downstream gene into the hepatocytes at the specific region of the liver. Because it has been known that there is a zonation in the liver, some factor(s) in the pericentral but not in the periportal areas may influence the expression of genes downstream of this regulatory element.
Immunostaining studies revealed that vast amounts of E1 and E2 protein were localized in the cytoplasm of mouse hepatocytes. This observation is consistent with the previous data obtained in cultured mammalian cells (Dubuisson et al., 1994; Ralston et al., 1993) or insect cells (Lanford et al., 1993) . Absence of E1 and E2 proteins in sera of the transgenic mice supports the idea that there was no secretion of these proteins from hepatocytes in vivo, although there remains the possibility that our detection method is not sensitive enough to detect a very low level of envelope proteins. This observation is also compatible with the previous finding in cultured mammalian cells in which E1 protein was retained in the endoplasmic reticular network (Ralston et al., 1993) . In human HCV infection, subviral envelope proteins have never been detected. In contrast, in the case of HBV infection, secreted small HBs antigen is readily detectable in patients' sera. It has also been known that large HBs antigen is retained in the endoplasmic reticulum of hepatocytes and is never secreted into blood (Chisari et al., 1986; Ou & Rutter, 1987) . It is therefore interesting to know whether or not the HCV envelope gene transgenic mice described here would develop liver injury and eventually hepatic turnouts, since transgenic mice which produce excessive amount of large HBs protein have been reported to develop liver tumours after continuous liver cell death as a consequence of the large envelope protein accumulation (Chisari et at., 1989) . By the age of 16 months, however, our HCV envelope transgenic mice have not developed liver cell injury or neoplastic lesions. The reasons for this may be; (i) levels of envelope proteins are too low to cause damage to hepatocytes, (it) mice are too young for the emergence of liver cell injury, or (iii) HCV envelope proteins do not have a potential to provoke liver cell damage even with their overexpression. The fact that no preneoplastic or neoplastic changes have appeared by 16 months of age in the livers of HCV envelope gene transgenic mice, in contrast to HBx gene transgenic mice in which HCC developed as a consequence of HBx protein overexpression driven by the same regulatory elements (Koike et al., 1994a) , suggests that HCV E1 or E2 proteinper se is not pathogenic when expressed in the mouse liver.
Although there is a report showing in vitro infection and replication of HCV (Shimizu et at., 1992) , the chimpanzee is still the only known non-human animal which supports the replication of HCV. This transgenic mouse would be a good animal model for the study of production, intracellular transport and assembly of HCV envelope proteins in liver cells. Furthermore, assembly of HCV particles may be studied by mating these transgenic mice with HCV core gene transgenic mice which we are now under way to establish. We can also use this envelope gene-transgenic mouse for deciphering the role of these proteins in the pathogenesis of hepatitis and extra-hepatic manifestations accompanying human HCV infection such as Sjogren's syndrome, glomerulonephritis or cryoglobulinaemia (Haddad et al., 1992; Johnson et al., 1993; Agnello et al., 1992) by transferring immunized cytotoxic T lymphocytes or antibodies.
